Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Biol Chem. May 26, 2015; 6(2): 16-27
Published online May 26, 2015. doi: 10.4331/wjbc.v6.i2.16
Published online May 26, 2015. doi: 10.4331/wjbc.v6.i2.16
Promise and challenges on the horizon of MET-targeted cancer therapeutics
Yu-Wen Zhang, Center for Cancer and Cell Biology, Van Andel Research Institute, Grand Rapids, MI 49503, United States
Author contributions: Zhang YW solely contributed to this manuscript.
Conflict-of-interest: There is no potential conflict of interest relevant to this article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Yu-Wen Zhang, MD, PhD, Center for Cancer and Cell Biology, Van Andel Research Institute, 333 Bostwick Ave NE, Grand Rapids, MI 49503, United States. yuwen.zhang@vai.org
Telephone: +1-616-2345532 Fax: +1-616-2345533
Received: January 20, 2015
Peer-review started: January 20, 2015
First decision: February 7, 2015
Revised: April 8, 2015
Accepted: April 16, 2015
Article in press: April 18, 2015
Published online: May 26, 2015
Peer-review started: January 20, 2015
First decision: February 7, 2015
Revised: April 8, 2015
Accepted: April 16, 2015
Article in press: April 18, 2015
Published online: May 26, 2015
Core Tip
Core tip: Aberrant activation of MET receptor tyrosine kinase signaling is frequently observed in many human cancers. Such activation not only affects cancer development and progression, but it also contributes to resistance against other cancer drugs. The inhibition of MET signaling is an attractive approach for cancer intervention, and pursuit of MET-targeted cancer therapeutics is underway. Even though promising results have been reported from various clinical trials, many challenges remain to be addressed before and even after the arrival of such drugs in the clinic.